Sentence: Bevacizumab , a monoclonal antibody targeting vascular endothelial growth factor , is the first antiangiogenic drug to show improved efficacy when used in combination with irinotecan and oxaliplatin for first- and second-line treatment of CRC .
Drug combination annotation:
[{'class': 'POS', 'spans': ['Bevacizumab', 'irinotecan', 'oxaliplatin'], 'is_context_needed': False}]